Search

everythinglearnresearchcommunity

for

Search:↓

Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.

IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.

Lenalidomide effectively and safely treats skin symptoms in pediatric lupus, reducing the need for prednisone.

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

Patients with fewer past treatments for alopecia areata respond better to baricitinib.

Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.

Abrocitinib may effectively treat Lichen Planopilaris.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.

Treating generalized granuloma annulare is difficult, with PUVA being the most effective option, but relapses are common.

New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.

Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.

17β-estradiol can reduce inflammation in the skin.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

Dupilumab effectively controls symptoms in infants with Netherton syndrome.

Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.

A woman with a rare autoimmune disorder had a blister on her eye and unique immune reaction, which was effectively treated with medication.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Pembrolizumab can cause unusual eyelash growth, but it may still be worth continuing if cancer treatment is effective.

Baricitinib was effective in treating alopecia areata in two major trials.

High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.

Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.

Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.

Infliximab can trigger lupus-like symptoms in Crohn's disease patients.

A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.